Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program Sickle Cell Disease Clinical Research Network |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00745420 |
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant is a treatment option for someone with a severe form of the disease. Prior to undergoing a transplant, people typically receive a conditioning regimen of high doses of chemotherapy and other medications to prepare the body to accept the transplant. A conditioning regimen that uses lower doses of chemotherapy and medications may be safer for transplant recipients. This study will evaluate the safety and effectiveness of blood stem cell transplants, using either bone marrow or umbilical cord blood from unrelated donors, in children with severe SCD who receive a reduced intensity conditioning regimen prior to the transplant.
Condition | Intervention | Phase |
---|---|---|
Hemoglobin SC Disease |
Biological: Hematopoietic Stem Cell Transplantation |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen (BMT CTN #0601) |
Estimated Enrollment: | 45 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | June 2015 |
Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: Hematopoietic Stem Cell Transplantation
The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
Regimen 1: Tacrolimus or cyclosporine beginning Day -3; methotrexate (7.5 mg/m2/day) on Days +1, +3, and +6; and methylprednisolone/prednisone on Days +7 to +28 followed by a taper if there is no GVHD. Regimen 2: Tacrolimus or cyclosporine beginning on Day -3, and mycophenolate mofetil (MMF) from Days -3 to +45 or to 7 days after neutrophil engraftment, whichever is later. |
SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and intense episodes of pain, also called "sickle cell crises." SCD is caused by an abnormal type of hemoglobin, which is a protein inside red blood cells that carries oxygen to vital organs, such as the brain, heart, lungs, and kidneys. Defective hemoglobin damages red blood cells. The damaged cells, in turn, can block blood flow in vessels and block oxygen and nutrients from reaching organs. For people with severe forms of SCD, one treatment option is a bone marrow transplant, which may correct the abnormal blood cell production problem. In most cases, bone marrow transplants are performed in people who have a healthy sibling with the same tissue type. If people do not have a sibling with the same tissue type, it is possible for them to receive a blood stem cell transplant from an unrelated donor through either a bone marrow transplant or an umbilical cord blood transplant.
Traditionally, people with SCD who are undergoing a bone marrow transplant receive high doses of chemotherapy and medications before the transplant as part of the conditioning regimen to prepare their immune system to accept the donor cells. Participants will experience fewer side effects with a reduced intensity conditioning regimen than with a more intense conditioning regimen. The purpose of this study is to determine the safety and effectiveness of blood stem cell transplants, using either bone marrow or umbilical cord blood from unrelated donors, in children with severe SCD who receive a reduced intensity conditioning regimen before the transplant. Specifically, researchers will evaluate whether the reduced intensity conditioning regimen is successful in allowing donor cells to settle and grow successfully, in preventing the production of SCD-damaged red blood cells, and in limiting SCD-related organ damage.
This study will enroll children with severe SCD who lack a sibling with the same tissue type who can serve as their donor. Participants will attend a study visit prior to the transplant to undergo a blood collection, neurocognitive testing to measure learning and brain function, and magnetic resonance angiogram (MRA) and magnetic resonance imaging (MRI) scans. Questionnaires to assess quality of life will also be completed. Twenty-two days before the transplant, participants will begin receiving a reduced intensity conditioning regimen of chemotherapy and medications to prepare them for the transplant. Eight days before the transplant, participants will be admitted to the hospital and will continue the conditioning regimen. Participants will then receive the umbilical cord blood or bone marrow transplant. After the transplant, participants will receive immunosuppression medications for at least 6 months to prevent graft-versus-host disease (GVHD), which occurs when the immune cells from the donated bone marrow or umbilical cord blood attack the body of the recipient. One week after the transplant, participants will receive granulocyte-colony-stimulating factor (G-CSF), which is a natural protein that increases the white blood cell count and helps protect the body against infections. Participants will receive G-CSF until their white blood cell level is normal again. Participants will remain in the hospital and be closely monitored for signs of infection or other complications until study researchers feel it is safe for them to return home.
After leaving the hospital, participants will attend study visits weekly during Weeks 1 to 8, at Day 60, weekly during Weeks 9 to 14, at Day 100, at Month 6, and at Years 1 and 2. At all study visits, a blood collection, medical history review, and physical exam will occur. In addition, at Day 100, Month 6, and Years 1 and 2, questionnaires to assess quality of life will be completed. At select visits the following procedures will also occur: lung function testing, heart function testing, MRA and MRI scans, and neurocognitive testing.
Ages Eligible for Study: | 3 Years to 16 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
SCD (genotype hemoglobin SS disease [Hb SS] or sickle ß [Sß°] thalassemia) with one or more of the following:
Exclusion Criteria:
Contact: Sandi Sykes | 301-251-1161 | bmtctn@emmes.com |
United States, Arizona | |
University of Arizona | Recruiting |
Tucson, Arizona, United States, 85724 | |
Contact: Michael Graham, MD 520-626-8278 mgraham@peds.arizona.edu | |
United States, California | |
University of California, San Francisco/Pediatric BMT | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Morton Coway, MD 415-476-2188 mcowan@peds.ucsf.edu | |
City of Hope National Medical Center | Active, not recruiting |
Duarte, California, United States, 91010 | |
Children's Hospital at Oakland | Active, not recruiting |
Oakland, California, United States, 94609 | |
United States, District of Columbia | |
Children's National Medical Center | Recruiting |
Washington, District of Columbia, United States, 20010 | |
Contact: Naynesh Kamani, MD 202-884-2169 nkamani@cnmc.org | |
United States, Florida | |
All Children's Hospital | Recruiting |
St. Petersburg, Florida, United States, 33701 | |
Contact: Michael Nieder, MD 727-767-6856 NiederM@allkids.org | |
Miami Children's Hospital | Active, not recruiting |
Miami, Florida, United States, 33155 | |
University of Miami | Active, not recruiting |
Miami, Florida, United States, 33136 | |
United States, Illinois | |
Children's Memorial Hospital - Northwestern | Recruiting |
Chicago, Illinois, United States, 60614 | |
Contact: Sonali Chaudhury, MD 773-880-4562 schaudhury@childrensmemorial.org | |
United States, Indiana | |
Indiana University, Riley Hospital for Children | Active, not recruiting |
Indianapolis, Indiana, United States, 46202 | |
United States, Mississippi | |
University of Mississippi Medical Center | Recruiting |
Jackson, Mississippi, United States, 39216 | |
Contact: Gail C Megason, MD 601-984-5220 gmegason@ped.umsmed.edu | |
United States, Missouri | |
Washington University | Recruiting |
St Louis, Missouri, United States, 63110 | |
Contact: Shalini Shenoy, MD 314-454-6018 shenoy@wustl.edu | |
United States, North Carolina | |
Duke University Medical Center | Active, not recruiting |
Durham, North Carolina, United States, 27705 | |
United States, Virginia | |
Virginia Commonwealth University | Recruiting |
Richmond, Virginia, United States, 23298 | |
Contact: Kamar Godder, MD, MPH 804-828-9605 kgodder@vcu.edu |
Study Chair: | Shalini Shenoy, MD | Washington University School of Medicine |
Study Chair: | Naynesh Kamani, MD | Childrens Research Institute |
Responsible Party: | National Heart, Lung, and Blood Institute ( Nancy DiFronzo, PhD, Project Officer ) |
Study ID Numbers: | 592, U01 HL069294 |
Study First Received: | August 29, 2008 |
Last Updated: | December 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00745420 |
Health Authority: | United States: Federal Government |
Sickle Cell Disease Sickle Cell Anemia |
Melphalan Prednisone Hemoglobin SC disease Cyclosporine Methylprednisolone Hematologic Diseases Hemoglobin SC Disease Anemia Anemia, Hemolytic Tacrolimus Fludarabine monophosphate |
Cyclosporins Sickle cell anemia Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Alemtuzumab Hemoglobinopathies Mycophenolate mofetil Methotrexate Fludarabine Hemoglobinopathy Anemia, Sickle Cell |